Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Exiqon A/S wins prestigious ERNST & YOUNG ENTREPENEUR OF THE YEAR Award
Exiqon selected as winner in the BIOTECH 2005 category


Copenhagen, November 21, 2005 – Exiqon A/S, a leading supplier of high-value gene expression analysis products announced today that it has won the Ernst & Young Entrepreneur Of The Year award in the category Biotech 2005. The prestigious award is created to identify and acknowledge the most successful and entrepreneurial Danish companies. A minimum growth of 15% in sales as well as growth in staff is among the key nomination criteria.

An impressive turnaround of the company in just 2 years, a successful business strategy and break-through research results were some of the points emphasized by the jury when Exiqon was named the best biotech company in Ernst & Young Entrepreneur of the Year competition. Exiqon’s ProbeLibrary™ product as well as its novel miRCURY™ microRNA detection product line were key elements of the successful growth of the company.

“We are very proud to receive this important award,” says Lars Kongsbak, President and CEO of Exiqon. “What we are seeing are the first results of Exiqon’s strategy to develop and market competitive products based on our LNA™ technology”, and adds, “We expect Exiqon’s revenue for 2005 to reach 5-6 million USD”.

The Ernst & Young award follows a successful past year where the Exiqon CEO won the award as Biotech Builder of the year, and Exiqon was named among the Top 100 most Innovative companies worldwide by the magazine RedHerring.


About microRNAs and LNATM
MicroRNAs are a novel class of regulatory RNA molecules with surprisingly widespread effects on gene regulation. Although recently identified as a class of molecules, initial studies indicate that microRNAs may regulate as much as 1/3 of all genes in the genome, thus comprising a up till now hidden level of regulation. Interestingly, microRNAs have already been found to play important roles in several types of cancers and in processes involved in cellular differentiation. In the cell, microRNAs are found in form of singlestranded RNA molecules, which are typically 20-25 nucleotides long in their active form.

LNAs are a class of nucleotide analogues that bind very strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like microRNAs, which is not possible using standard DNA-based detection probes.


About Exiqon
Exiqon is a leading supplier of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon’s rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on www.exiqon.com or through distributors and partners its proprietary Locked Nucleic Acids (LNA™) and Anthraquinone (AQ-Link™) technologies through industry leaders. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark. Please visit our web-site at www.exiqon.com.
xx


Publisher Contact Information:

Exiqon A/S
+45 45 65 04 54
sme@exiqon.com

Company profile of Exiqon A/S
Past press releases of Exiqon A/S.

Data


26,368
Tech investments
From our Online Data Service
17,022
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.